SLC45A3
Overview
SLC45A3 (also known as PROSTEIN) encodes a prostate-specific androgen-regulated membrane protein. In prostate cancer, SLC45A3 is notable as an alternative androgen-regulated 5’ fusion partner in ETS-family gene fusions, similar to the dominant TMPRSS2 fusion partner. These fusions place ETS transcription factors (such as ERG, ETV1) under androgen-regulated promoter control.
Alterations observed in the corpus
- Alternative androgen-regulated 5’ fusion partner in ETS-family gene fusions in primary prostate cancer; alternative to the dominant TMPRSS2 partner PMID:26544944
- SLC45A3–ELK4 non-recurrent in-frame fusion detected in a periampullary tumor; previously characterized as a prostate-cancer prognostic marker PMID:26804919
Cancer types (linked)
- PRAD (Prostate Adenocarcinoma): Acts as an androgen-regulated 5’ fusion partner for ETS genes in a subset of primary prostate tumors; identified in the TCGA prostate adenocarcinoma comprehensive genomic characterization PMID:26544944
Co-occurrence and mutual exclusivity
- Functions in parallel with TMPRSS2 and NDRG1 as an androgen-regulated promoter donor for ETS fusions; different fusion partners define molecular subtypes of prostate cancer PMID:26544944
Therapeutic relevance
- Androgen-regulated fusion partners including SLC45A3 imply that androgen-deprivation therapy could reduce ETS-fusion transcript levels; subtype-stratified responses to AR-directed therapies such as enzalutamide and abiraterone may be relevant PMID:26544944
Open questions
- The frequency and specific ETS partners fusing to SLC45A3 in the TCGA prostate cohort are not precisely enumerated relative to TMPRSS2-fusions PMID:26544944
Sources
This page was processed by entity-page-writer on 2026-05-14. - PMID:26804919
This page was processed by wiki-cli on 2026-05-14.